RxDoctor Payments Data

Jonathan Levine, MD

Internal Medicine · Charlotte, NCNPI 1194712240

Payments from drug & device makers

$827in general payments, 2019–2025

Across 9 payments — averaging $91.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$122
  • Amgen$122
  • Novartis$117
  • Sanofi$110
  • Bristol Myers Squibb$110
  • Apellis Pharmaceuticals, Inc.$108
  • plus $138 from 3 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$47,042
Medicare patients
336
Services billed
561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate56$1,010,186
CalquenceAcalabrutinib Maleate49$614,305
ImbruvicaIbrutinib33$529,424
EmpaveliPegcetacoplan13$522,428
BrukinsaZanubrutinib63$460,258
Lenalidomide16$238,368
DopteletAvatrombopag Maleate12$213,679
EliquisApixaban115$89,846
Imatinib Mesylate15$85,234
GleevecImatinib Mesylate12$71,296
XareltoRivaroxaban92$68,209
Hydroxyurea106$1,761
Acyclovir59$1,220
Warfarin Sodium39$651
Oxycodone Hcl29$469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$122$614,30549 claims
Apellis Pharmaceuticals, Inc.Empaveli$108$522,42813 claims
NovartisGleevec$117$71,29612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →